CLICK TO SHARE
Good morning, and welcome to the AngioDynamics third-quarter fiscal-year 2019 earnings call. [Operator instructions] As a reminder, this conference call is being recorded. The news release detailing the third-quarter results crossed the wire earlier this morning and is available on the company's website. This conference call is also being broadcast live over the Internet at the Investors section of the company's website at www.angiodynamics.com, and the webcast replay of the call will be available at the same site approximately one hour after the end of today's call.
Before we begin, I would like to caution listeners that during the course of this conference call, the company will make projections or forward-looking statements regarding future events, including statements about expected revenue, adjusted earnings and free cash flow for fiscal year 2019. Management encourages you to review the company's past and future filings with the SEC, including, without limitation, the company's forms 10-Q and 10-K, which identify specific factors that may cause the actual results or events to differ materially from those described in the forward-looking statements. A slide package offering insight into the company's financial results is also available on the Investors section of the company's website under events and presentations. This presentation should be read in conjunction with the press release discussing the company's operating results and financial performance during this morning's conference call.
I'd now like to turn the call over to Jim Clemmer, AngioDynamics' president and chief executive officer. Mr. Clemmer?
Thanks, Rob. Good morning, everyone, and thanks for joining us today for AngioDynamics third-quarter fiscal 2019 earnings call. Joining me today on the call will be Michael Greiner, AngioDynamics' executive vice president and chief financial officer; and Stephen Trowbridge, senior vice president and general counsel, who is also the leader of our clinical team. Michael is under the weather today and will not be doing the financial portion of the call but is with us to answer any questions that you may have during the Q&A portion of our call.
Today, I will provide a brief overview of our operating highlights and financial performance for the quarter. Before I close our prepared remarks, we'll have a discussion of the NanoKnife pancreatic cancer DIRECT study. Stephen has joined us to answer specific questions that you may have related to the approval of this study that we announced yesterday morning. Overall, we are really pleased with our results for the third quarter.
Post a comment.
CLICK TO SHARE
COMMENTS VIA TWITTER
@Mattbarone6 They restated the target in the last conference call. "We are all working together toward our corporat… https://t.co/zLozmwCTtz
Edited Transcript of HQY earnings conference call or presentation 3-Sep-19 9:00pm GMT https://t.co/NN01kTKGTh
New Media Investment Group Inc (NEWM) Q4 2018 Earnings Conference Call Transcript https://t.co/hi5ypIUSp8 https://t.co/SMM4EBsWUi
Edited Transcript of TFX earnings conference call or presentation 2-May-19 12:00pm GMT https://t.co/m7CsrTTUqq
Edited Transcript of HOLX earnings conference call or presentation 31-Jul-19 8:30pm GMT https://t.co/O2owYFFWSg